RBMS2 Antibody

What applications are validated for RBMS2 antibodies?

RBMS2 antibodies have been validated for multiple research applications including:

• Western blot (WB): Recommended dilutions typically range from 1:500-1:6000, depending on the specific antibody

• Immunohistochemistry (IHC-P): Recommended dilutions of 1:20-1:200 to 1:50-1:300

• Immunofluorescence (IF): Successfully used with specific monoclonal antibodies like clone 3B12

• ELISA: Typically using dilutions of 1:2000-1:10000

• Immunoprecipitation (IP): Validated with specific antibodies such as the B-4 clone

Methodological Guidance: For optimal results in Western blot applications, researchers should validate antibody performance in their specific cell lines of interest. Positive WB detection has been confirmed in multiple cell lines including NCI-H1299, U2OS, LNCaP, A549, and HeLa cells .

What are the recommended storage and handling procedures?

Most RBMS2 antibodies require storage at -20°C in appropriate buffer conditions:

• Typical formulation includes PBS with 50% glycerol and stabilizing agents (0.02-0.03% sodium azide)

• Aliquoting is generally unnecessary for -20°C storage for certain antibodies

• Avoid repeated freeze-thaw cycles to maintain antibody performance

• Smaller preparations (e.g., 20μl sizes) may contain 0.1% BSA as an additional stabilizer

What is the biological significance of RBMS2 that makes it an important research target?

RBMS2 functions as:

• A key player in post-transcriptional regulation of gene expression

• A tumor suppressor in several cancer types, including breast cancer and kidney renal clear cell carcinoma (ccRCC)

• A stabilizer of P21 mRNA by binding to the AU-rich element of the 3′-UTR region, inhibiting cancer cell proliferation

Research findings demonstrate that:

• RBMS2 expression is negatively associated with adverse clinico-pathological features in ccRCC, including advanced TNM stage

• RBMS2 serves as a prognostic predictor for clinical outcomes in ccRCC, as evidenced by both univariate and multivariate analyses

• Overexpression of RBMS2 inhibits ccRCC cell proliferation and migration

• In breast cancer studies, RBMS2 has been shown to induce cell cycle arrest in G1 phase

Research Implication: RBMS2's tumor-suppressive role makes it a potential therapeutic target for cancer treatment, particularly in breast cancer and ccRCC.

How should RNA immunoprecipitation (RIP) be optimized for RBMS2 studies?

For effective RNA immunoprecipitation to study RBMS2-RNA interactions:

• Cell Lysate Preparation:

  • Prepare cell lysates from target cells (e.g., SUM-1315 and MCF-7) using RNA immunoprecipitation lysis buffer at 4°C

  • Use 5μg of anti-RBMS2 antibody or rabbit IgG (as control) and incubate overnight at 4°C

• RNA-Protein Complex Collection:

  • Collect RNA-protein immunocomplexes using protein A/G magnetic beads

  • Perform RNA purification from the immunocomplexes

  • Use PCR and qRT-PCR to measure levels of target transcripts (e.g., P21) and controls (e.g., β-actin) in the immunocomplexes

Critical Considerations: Temperature control (maintaining 4°C throughout the process) and appropriate negative controls are essential for reliable results. The selection of an appropriate RBMS2 antibody with validated RIP performance is crucial.

How can researchers effectively design studies to investigate RBMS2's role in RNA stability?

To study RBMS2's effect on RNA stability:

• RNA Stability Assay Protocol:

  • Culture RBMS2-overexpressing cell lines and their control cell lines in 6-well plates

  • Add actinomycin D (ActD) at 5μg/ml at different time points (0h, 2h, 4h, and 8h) before collection

  • Isolate total RNA and perform qRT-PCR to quantify the relative levels of target transcripts (e.g., P21)

• Dual-Luciferase Reporter Assay:

  • Construct a pGL3 reporter containing the 3′-UTR region or AREs mutant region of the target transcript

  • Co-transfect with Renilla luciferase vector (pRL-TK) as an internal control

  • For mutant controls, change the AUUUA motif in target 3′-UTR region into AGGGA

  • After 48h, harvest cells to measure luciferase intensity

Data Analysis Tip: Plot RNA decay curves to calculate half-life, and perform statistical analysis to determine significant differences between RBMS2-overexpressing and control cells.

What are the best practices for immunohistochemistry using RBMS2 antibodies?

For optimal IHC results with RBMS2 antibodies:

Troubleshooting Tip: Include negative controls by omitting the primary antibody to assess background staining.

How can RBMS2 expression levels be accurately quantified in different cancer models?

For precise quantification of RBMS2 expression:

• Western Blot Analysis:

  • Recommended antibody dilutions range from 1:500-1:2000 for polyclonal antibodies and 1:1000-1:6000 for monoclonal antibodies

  • Use appropriate positive controls: NCI-H1299, U2OS, LNCaP, A549, and HeLa cells have been validated for RBMS2 expression

  • Expected molecular weight: 44 kDa

• qRT-PCR Analysis:

  • Isolate total RNA using Trizol reagent

  • Reverse-transcribe using standard protocols (typically 1000 ng RNA)

  • Use β-actin as an endogenous control

  • Compare expression levels between cancer tissues and adjacent normal tissues

Experimental Design Table for RBMS2 Expression Analysis in Cancer Models:

How does RBMS2 expression correlate with clinical outcomes in cancer patients?

Studies have revealed significant correlations between RBMS2 expression and clinical parameters:

• ccRCC (Kidney Cancer):

  • Lower RBMS2 expression correlates with higher histologic grade (p<0.001)

  • Lower RBMS2 expression associates with older age (>60 years, p=0.035)

  • Lower RBMS2 expression correlates with altered serum calcium levels (p=0.002)

  Survival Analysis:

  • High RBMS2 expression significantly associates with better disease-specific survival (hazard ratio = 0.387, p=0.004)

  • High RBMS2 expression correlates with improved progression-free survival (hazard ratio = 0.527, p=0.02)

• Breast Cancer:

  • RBMS2 is significantly downregulated in breast cancer compared to normal tissues (log fold change -1.21, FDR<0.05)

  • Higher RBMS2 expression correlates with favorable recurrence-free survival (HR 0.72, p<0.05)

  • Tumors with high RBMS2 expression tend to be smaller in size

Research Implication: The strong correlation between RBMS2 expression and clinical outcomes suggests its potential utility as a prognostic biomarker in multiple cancer types.

What cellular mechanisms explain RBMS2's tumor-suppressive role?

The tumor-suppressive function of RBMS2 is mediated through several mechanisms:

• P21 mRNA Stabilization:

  • RBMS2 directly binds to the AU-rich element in the 3′-UTR region of P21 mRNA

  • This binding stabilizes P21 mRNA, increasing P21 protein levels

  • Elevated P21 promotes cell cycle arrest and inhibits proliferation

• Cell Cycle Regulation:

  • RBMS2 overexpression induces G1 phase arrest in breast cancer cell lines

  • This effect can be rescued by P21 knockdown, confirming the P21-dependent mechanism

• Impact on Tumor Growth:

  • In vivo studies demonstrated that RBMS2 overexpression significantly reduces tumor volume and weight in mouse xenograft models

  • RBMS2 overexpression inhibits colony formation ability in vitro

Methodological Note: These mechanisms were elucidated using a combination of techniques including RNA immunoprecipitation, dual-luciferase reporter assays, RNA stability assays, cell cycle analysis by flow cytometry, and in vivo tumor models.

How can researchers validate the specificity of RBMS2 antibodies?

To ensure antibody specificity:

• Knockdown/Knockout Validation:

  • Perform Western blot analysis comparing wild-type cells with RBMS2 knockdown or knockout cells

  • CRISPR/Cas9 KO systems are available for human and mouse models

  • siRNA knockdown can be performed using validated sequences

• Overexpression Validation:

  • Compare control cells with RBMS2-overexpressing cells

  • Check for increased band intensity at the expected molecular weight (44 kDa)

• Cross-Reactivity Testing:

  • Verify antibody reactivity with human and mouse samples as appropriate

  • Many RBMS2 antibodies have been validated for reactivity with human samples, and some also for mouse samples

Quality Control Recommendation: When switching antibody lots or sources, perform side-by-side comparisons to ensure consistent performance in your experimental system.

What are the key considerations when selecting RBMS2 antibodies for specific research applications?

Critical factors to consider include:

• Epitope Recognition:

  • Different antibodies target distinct epitope regions (e.g., 194-244 aa, 271-289 aa)

  • For studying specific domains or interactions, select antibodies targeting relevant regions

• Clonality:

  • Polyclonal antibodies (e.g., PACO35322) offer broad epitope recognition

  • Monoclonal antibodies (e.g., clone 3B12) provide higher specificity and consistency

• Validated Applications:

  • Some antibodies are validated for multiple applications (WB, IHC, IF, IP)

  • Others may be optimized for specific techniques only

• Species Reactivity:

  • Most RBMS2 antibodies are validated for human samples

  • Some also react with mouse samples

  • For non-human primate research, cross-reactivity may need to be independently verified

Selection Matrix for Common Research Applications:

By following these recommendations and methodological guidelines, researchers can effectively utilize RBMS2 antibodies for investigating its roles in cancer biology and other cellular processes.